These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cell-specific MAPT gene expression is preserved in neuronal and glial tau cytopathologies in progressive supranuclear palsy. Forrest SL; Lee S; Nassir N; Martinez-Valbuena I; Sackmann V; Li J; Ahmed A; Tartaglia MC; Ittner LM; Lang AE; Uddin M; Kovacs GG Acta Neuropathol; 2023 Sep; 146(3):395-414. PubMed ID: 37354322 [TBL] [Abstract][Full Text] [Related]
3. Cross species systems biology discovers glial DDR2, STOM, and KANK2 as therapeutic targets in progressive supranuclear palsy. Min Y; Wang X; İş Ö; Patel TA; Gao J; Reddy JS; Quicksall ZS; Nguyen T; Lin S; Tutor-New FQ; Chalk JL; Mitchell AO; Crook JE; Nelson PT; Van Eldik LJ; Golde TE; Carrasquillo MM; Dickson DW; Zhang K; Allen M; Ertekin-Taner N Nat Commun; 2023 Nov; 14(1):6801. PubMed ID: 37919278 [TBL] [Abstract][Full Text] [Related]
4. Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies. Langerscheidt F; Wied T; Al Kabbani MA; van Eimeren T; Wunderlich G; Zempel H J Neurol; 2024 Jun; 271(6):2992-3018. PubMed ID: 38554150 [TBL] [Abstract][Full Text] [Related]
5. Clinical Phenotypes of Progressive Supranuclear Palsy-The Differences in Interleukin Patterns. Madetko-Alster N; Otto-Ślusarczyk D; Wiercińska-Drapało A; Koziorowski D; Szlufik S; Samborska-Ćwik J; Struga M; Friedman A; Alster P Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894815 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic and therapeutic targeting of pathological tau proteins in neurodegenerative disorders. Sahara N; Higuchi M FEBS Open Bio; 2024 Feb; 14(2):165-180. PubMed ID: 37746832 [TBL] [Abstract][Full Text] [Related]
7. Automated Detection of Speech Timing Alterations in Autopsy-Confirmed Nonfluent/Agrammatic Variant Primary Progressive Aphasia. García AM; Welch AE; Mandelli ML; Henry ML; Lukic S; Torres Prioris MJ; Deleon J; Ratnasiri BM; Lorca-Puls DL; Miller BL; Seeley W; Vogel AP; Gorno-Tempini ML Neurology; 2022 Aug; 99(5):e500-e511. PubMed ID: 35914945 [TBL] [Abstract][Full Text] [Related]
8. Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43. Tarutani A; Adachi T; Akatsu H; Hashizume Y; Hasegawa K; Saito Y; Robinson AC; Mann DMA; Yoshida M; Murayama S; Hasegawa M Acta Neuropathol; 2022 Jun; 143(6):613-640. PubMed ID: 35513543 [TBL] [Abstract][Full Text] [Related]
10. Deep Learning-Based Image Classification in Differentiating Tufted Astrocytes, Astrocytic Plaques, and Neuritic Plaques. Koga S; Ghayal NB; Dickson DW J Neuropathol Exp Neurol; 2021 Mar; 80(4):306-312. PubMed ID: 33570124 [TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry analysis of tau and amyloid-beta in iPSC-derived models of Alzheimer's disease and dementia. Arber C; Alatza A; Leckey CA; Paterson RW; Zetterberg H; Wray S J Neurochem; 2021 Oct; 159(2):305-317. PubMed ID: 33539581 [TBL] [Abstract][Full Text] [Related]
12. Progressive Supranuclear Palsy and Corticobasal Degeneration. Coughlin DG; Dickson DW; Josephs KA; Litvan I Adv Exp Med Biol; 2021; 1281():151-176. PubMed ID: 33433875 [TBL] [Abstract][Full Text] [Related]
13. Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies. Alausa A; Ogundepo S; Olaleke B; Adeyemi R; Olatinwo M; Ismail A Chin Med; 2021 Jan; 16(1):1. PubMed ID: 33407732 [TBL] [Abstract][Full Text] [Related]
14. Cellular Biology of Tau Diversity and Pathogenic Conformers. Kang SG; Eskandari-Sedighi G; Hromadkova L; Safar JG; Westaway D Front Neurol; 2020; 11():590199. PubMed ID: 33304310 [TBL] [Abstract][Full Text] [Related]
16. Progressive supranuclear palsy: Advances in diagnosis and management. Coughlin DG; Litvan I Parkinsonism Relat Disord; 2020 Apr; 73():105-116. PubMed ID: 32487421 [TBL] [Abstract][Full Text] [Related]
17. Astroglia and Tau: New Perspectives. Kovacs GG Front Aging Neurosci; 2020; 12():96. PubMed ID: 32327993 [TBL] [Abstract][Full Text] [Related]
18. Factors associated with development and distribution of granular/fuzzy astrocytes in neurodegenerative diseases. Miki T; Yokota O; Haraguchi T; Ishizu H; Hasegawa M; Ishihara T; Ueno SI; Takenoshita S; Terada S; Yamada N Brain Pathol; 2020 Jul; 30(4):811-830. PubMed ID: 32293067 [TBL] [Abstract][Full Text] [Related]
19. Tau immunoreactivity in peripheral tissues of human aging and select tauopathies. Dugger BN; Hoffman BR; Scroggins A; Serrano GE; Adler CH; Shill HA; Belden CM; Sabbagh MN; Caviness JN; Driver Dunckley E; Beach TG Neurosci Lett; 2019 Mar; 696():132-139. PubMed ID: 30579993 [TBL] [Abstract][Full Text] [Related]
20. Tau in neurodegenerative disease. Gao YL; Wang N; Sun FR; Cao XP; Zhang W; Yu JT Ann Transl Med; 2018 May; 6(10):175. PubMed ID: 29951497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]